• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
BlackRock TCP Capital Corp. - Closed End Fund
Ramaco Resources, Inc. - Class A Common Stock
SLM Corporation - Floating Rate Non-Cumulative Preferred Stock, Series B
Edit Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Skye Bioscience, Inc. - Common Stock (NQ:SKYE)

0.7000 -0.0868 (-11.03%)
Delayed Quote Updated: 4:00 PM EST, Nov 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 289,024
Open 0.8460
Bid (Size) 0.5420 (1,300)
Ask (Size) 0.7650 (100)
Prev. Close 0.7868
Today's Range 0.4842 - 0.8460
52wk Range 0.4842 - 11.04
Shares Outstanding 417,247,333
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
SKYE Stock Alert: Halper Sadeh LLC is Investigating Whether Skye Bioscience, Inc. is Obtaining a Fair Price for its Shareholders
November 18, 2026
From Halper Sadeh LLC
Via Business Wire
The trading volume of these stocks is deviating from the norm in today's session. ↗
August 21, 2026
Via Chartmill

Performance

52-Week Range 93.7% below 52-week high
0.7000
0.4852W Low 11.0452W High
1 Week 44.0% below 1-week high
0.481W Low 1.251W High

Skye Bioscience, Inc. - Common Stock (SKYE) traded between $0.48 and $11.04 over the past 52 weeks and last traded at $0.70, 93.7% below its 52-week high. Over the past week it ranged between $0.48 and $1.25.

Past 12 Months
-34.3%
-56.8%
-67.7%
-89.4%
-90.0%
-92.5%
1W -$0.36
1M -$0.92
3M -$1.47
6M -$5.88
YTD -$6.33
1Y -$8.62

SKYE was -92.5% over the past year, -89.4% over six months, -90.0% year to date, -34.3% in the last week.

12 Months vs Market
SKYE
-92.5%
DIA
+4.0%
SPY
+4.7%
QQQ
+3.1%
IWM
+8.9%

Over the past 12 months SKYE returned -92.5% versus DIA (Dow) +4.0%, SPY (S&P 500) +4.7%, QQQ (Nasdaq 100) +3.1% and IWM (Russell 2000) +8.9%.

Volume & Liquidity 3.28× 3-mo avg
Today 289,024 3-mo avg 88.2K
1W
111.7K
1M
132.0K
3M
88.2K
6M
74.8K
YTD
66.6K
1Y
65.2K

SKYE most recently traded 289,024 shares against a 3-month average daily volume of 88.2K.

More News

Read More
Unusual volume stocks in Wednesday's session ↗
August 19, 2026
Via Chartmill
Keep an eye on the top gainers and losers in Friday's session. ↗
August 14, 2026
Via Chartmill
These stocks have an unusual volume in today's session ↗
March 11, 2026
Via Chartmill
What's going on in today's pre-market session ↗
March 11, 2026
Via Chartmill
Get insights into the top gainers and losers of Tuesday's after-hours session. ↗
March 10, 2026
Via Chartmill
News headline image
SKYE DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important January 16 Deadline in Securities Class Action – SKYE
January 15, 2026
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
SKYE BIOSCIENCE FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urgently Reminds Skye Bioscience, Inc. Stockholders to Contact the Firm Before January 16th
January 15, 2026
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm
January 15, 2026
From Schall Law
Via GlobeNewswire
News headline image
INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience
January 14, 2026
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Skye Bioscience, Inc. (NASDAQ: SKYE) Investors to Inquire About a Securities Fraud Class Action by January 16, 2026
January 14, 2026
From Berger Montague
Via GlobeNewswire
News headline image
SKYE DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important January 16 Deadline in Securities Class Action – SKYE
January 12, 2026
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
SKYE BIOSCIENCE CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Urgently Reminds Skye Bioscience, Inc. Stockholders to Contact the Firm Before January 16th
January 12, 2026
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm
January 12, 2026
From Schall Law
Via GlobeNewswire
News headline image
SKYE Deadline: Rosen Law Firm Urges Skye Bioscience, Inc. (NASDAQ: SKYE) Stockholders to Contact the Firm for Information About Their Rights
January 09, 2026
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
SKYE INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience
January 09, 2026
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm
January 08, 2026
From Schall Law
Via GlobeNewswire
News headline image
SKYE CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Skye Bioscience, Inc. and Encourages Investors to Contact the Firm
January 06, 2026
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm
January 05, 2026
From Schall Law
Via GlobeNewswire
News headline image
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience
January 02, 2026
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm
January 01, 2026
From Schall Law
Via GlobeNewswire
News headline image
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm
December 29, 2025
From Schall Law
Via GlobeNewswire
News headline image
NASDAQ: SKYE INVESTOR ALERT: Berger Montague Advises Skye Bioscience, Inc. (NASDAQ: SKYE) Investors of a January 16, 2026 Deadline
December 29, 2025
From Berger Montague
Via GlobeNewswire
News headline image
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm
December 26, 2025
From Schall Law
Via GlobeNewswire

Frequently Asked Questions

Is Skye Bioscience, Inc. - Common Stock publicly traded?
Yes, Skye Bioscience, Inc. - Common Stock is publicly traded.
What exchange does Skye Bioscience, Inc. - Common Stock trade on?
Skye Bioscience, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Skye Bioscience, Inc. - Common Stock?
The ticker symbol for Skye Bioscience, Inc. - Common Stock is SKYE on the Nasdaq Stock Market
What is the current price of Skye Bioscience, Inc. - Common Stock?
The current price of Skye Bioscience, Inc. - Common Stock is 0.7000
When was Skye Bioscience, Inc. - Common Stock last traded?
The last trade of Skye Bioscience, Inc. - Common Stock was at 11/20/26 04:00 PM ET
What is the market capitalization of Skye Bioscience, Inc. - Common Stock?
The market capitalization of Skye Bioscience, Inc. - Common Stock is 292.07M
How many shares of Skye Bioscience, Inc. - Common Stock are outstanding?
Skye Bioscience, Inc. - Common Stock has 292M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap